Research and Markets (http://www.researchandmarkets.com/research/6n7swq/invega) has announced the addition of the "Invega (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.
Invega (paliperidone; Janssen) is the 9-hydroxy metabolite of risperidone and thus shares a similar pharmacologic profile with Risperdal. Invega is a D2 and 5-HT2A antagonist, and though it lacks activity on M1 and M3 muscarinic receptors, it also blocks a1 and a2 adrenergic, and H1 histaminergic receptors.
Scope
- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Invega including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Invega for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan
Key Topics Covered:
1 List of Tables
2 Introduction
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Diagnosis
4.2 Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Invega (paliperidone)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
For more information visit http://www.researchandmarkets.com/research/6n7swq/invega
Contacts:
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central
Nervous System
